Michael Klichinsky net worth and biography

Michael Klichinsky Biography and Net Worth

Insider of Carisma Therapeutics

Michael Klichinsky, Pharm.D., Ph.D. has served as Carisma’s Chief Scientific Officer since April 2022. He co-founded Carisma in 2016 and served as Vice President of Discovery of Carisma from October 2018 to April 2021 and as Senior Vice President of Research of Carisma from April 2021 to April 2022. Dr. Klichinsky received a Doctor of Pharmacy from the University of Sciences in Philadelphia and a Ph.D. in Pharmacology from the University of Pennsylvania.

What is Michael Klichinsky's net worth?: The estimated net worth of Michael Klichinsky is at least $159.67 as of October 1st, 2025. Klichinsky owns 319,347 shares of Carisma Therapeutics stock worth more than $160 as of October 13th. This net worth estimate does not reflect any other investments that Klichinsky may own. Learn More about Michael Klichinsky's net worth.
How do I contact Michael Klichinsky?: The corporate mailing address for Klichinsky and other Carisma Therapeutics executives is 3675 Market Street, Philadelphia, PA, 19104. Carisma Therapeutics can also be reached via phone at 617-444-8550 and via email at [email protected]. Learn More on Michael Klichinsky's contact information.
Has Michael Klichinsky been buying or selling shares of Carisma Therapeutics?: Michael Klichinsky has not been actively trading shares of Carisma Therapeutics during the last ninety days. Most recently, Michael Klichinsky sold 56,982 shares of the business's stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $0.25, for a transaction totalling $14,245.50. Learn More on Michael Klichinsky's trading history.

Michael Klichinsky Insider Trading History at Carisma Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/7/2025	Sell	56,982	$0.25	$14,245.50
10/3/2025	Sell	119,347	$0.26	$31,030.22
10/2/2025	Sell	200,000	$0.25	$50,000.00	119,347
10/1/2025	Sell	165,000	$0.26	$42,900.00	319,347

Michael Klichinsky Buying and Selling Activity at Carisma Therapeutics

Carisma Therapeutics Company Overview

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Today's Range

Now: $0.00

$0.00

50 Day Range

MA: N/A

2 Week Range

Now: $0.00

$0.00

$0.10

Volume

4,455 shs

Average Volume

55,631 shs

Market Capitalization

$20.92 thousand

P/E Ratio

0.00

Dividend Yield

N/A

Beta